344 related articles for article (PubMed ID: 3920474)
1. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
Stribling D; Mirrlees DJ; Harrison HE; Earl DC
Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
[TBL] [Abstract][Full Text] [Related]
2. The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
Poulsom R; Mirrlees DJ; Earl DC; Heath H
Exp Eye Res; 1983 May; 36(5):751-60. PubMed ID: 6406254
[TBL] [Abstract][Full Text] [Related]
3. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat.
Ao S; Shingu Y; Kikuchi C; Takano Y; Nomura K; Fujiwara T; Ohkubo Y; Notsu Y; Yamaguchi I
Metabolism; 1991 Jan; 40(1):77-87. PubMed ID: 1898618
[TBL] [Abstract][Full Text] [Related]
5. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Cameron NE; Cotter MA; Robertson S
Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
[TBL] [Abstract][Full Text] [Related]
6. Sorbitol metabolism in the retina, optic nerve, and sural nerve of diabetic rats treated with an aldose reductase inhibitor.
Naeser P; Brolin SE; Eriksson UJ
Metabolism; 1988 Dec; 37(12):1143-5. PubMed ID: 3143049
[TBL] [Abstract][Full Text] [Related]
7. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
[No Abstract] [Full Text] [Related]
9. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
10. Fast anterograde axonal transport in wasted and non-wasted diabetic rats; effects of aldose reductase inhibition.
Whiteley SJ; Townsend J; Tomlinson DR; Willars GB
Diabetes Res; 1986 Nov; 3(9):447-52. PubMed ID: 2435444
[TBL] [Abstract][Full Text] [Related]
11. Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.
Dahlin LB; Archer DR; McLean WG
Diabetologia; 1987 Jun; 30(6):414-8. PubMed ID: 2445613
[TBL] [Abstract][Full Text] [Related]
12. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D
Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
[TBL] [Abstract][Full Text] [Related]
13. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V
J Pharmacol Sci; 2009 Feb; 109(2):203-10. PubMed ID: 19212096
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of aldose reductase in five tissues of the streptozotocin-diabetic rat.
Poulsom R; Heath H
Biochem Pharmacol; 1983 May; 32(9):1495-9. PubMed ID: 6407486
[TBL] [Abstract][Full Text] [Related]
15. Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil.
Willars GB; Townsend J; Tomlinson DR; Compton AM; Churchill RD
Metabolism; 1988 May; 37(5):442-9. PubMed ID: 2452959
[TBL] [Abstract][Full Text] [Related]
16. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
Malamas MS; Hohman TC; Millen J
J Med Chem; 1994 Jun; 37(13):2043-58. PubMed ID: 8027986
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.
Matsui T; Nakamura Y; Ishikawa H; Matsuura A; Kobayashi F
Jpn J Pharmacol; 1994 Feb; 64(2):115-24. PubMed ID: 8028228
[TBL] [Abstract][Full Text] [Related]
18. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
Gillon KR; Hawthorne JN; Tomlinson DR
Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
20. Statil-sensitive polyol formation in nerve of galactose-fed mice.
Calcutt NA; Willars GB; Tomlinson DR
Metabolism; 1988 May; 37(5):450-3. PubMed ID: 3130544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
